CLINICAL OUTCOMES AND HOSPITAL COSTS ASSOCIATED WITH EMPIRICAL TREATMENT OF HOSPITAL-ACQUIRED PNEUMONIA WITH VANCOMYCIN OR LINEZOLID IN A CHINESE TERTIARY CARE HOSPITAL- A RETROSPECTIVE COHORT STUDY
Author(s)
Yang Y1, Song Y2, Chen W3, Liu W4, Wang K4, Li X5, Wang K6, Papadimitropoulos M7, Montgomery W8
1Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China, 2Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China, 3University of Toronto, Toronto, ON, Canada, 4Eli Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, China, 5VitalStrategic Research Institute, Shanghai, China, 6Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China, 7Eli Lilly Canada, Toronto, ON, Canada, 8Eli Lilly Australia Pty Ltd., West Ryde, Australia
Conference/Value in Health Info
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PIN14
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine), Respiratory-Related Disorders